Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
Home Client Center Publications

Academic literature published using Medicilon selenoamino acid medium products

2023-07-18
|
Page View：

Medicilon provide complete sets of M9 selenomethionine (SeMET) medium for IPTG-induced E.coli expression system, production of selenomethionine-labeled protein and protein crystallography using multi-wavelength anomalous diffraction (MAD).

Academic literature published using Medicilon selenoamino acid medium products.jpg

• Nature. 2008 Oct 9;455(7214):822-5.

• Nat Microbiol. 2020 May;5(5):706-714.

• Nucleic Acids Res. 2019 Jun 4;47(10):5420-5428.

• Nucleic Acids Res. 2016 Jan 29;44(2):595-607.

• Nucleic Acids Res. 2012 Feb;40(4):1868-78.

• Nucleic Acids Res. 2010 Jun;38(10):3432-40.

• Nat Struct Mol Biol. 2014 Aug;21(8):686-695.

• Nat Struct Mol Biol. 2012 Dec;19(12):1316-23.

• Nat Struct Mol Biol. 2009 Apr;16(4):421-9.

• Nat Chem Biol. 2018 May;14(5):466-473.

• Nat Commun. 2018 Jan 9;9(1):112.

• Nat Commun. 2016 Jan 5;7:10175.

• Nat Commun. 2016 Apr 22;7:11343.

• Nat Commun. 2014 Jun 13;5:4068.

• Sci Adv. 2016 Oct 21;2(10):e1601317.

• Mol Syst Biol. 2016 Dec 16;12(12):893.

• Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):18459-64.

• Elife. 2018 May 24;7:e27829.

• mBio. 2021 Mar 16;12(2):e03287-20.

• mBio. 2021 Feb 9;12(1):e02705-20.

• mBio. 2015 Aug 11;6(4):e00806.

• Acta Crystallogr D Struct Biol. 2020 Feb 1;76(Pt 2):166-175.

• Protein Sci. 2020 Mar;29(3):711-722.

• FEBS J. 2016 Jun;283(12):2206-18.

• FEBS J. 2008 Oct;275(19):4824-35.

• Environ Microbiol. 2014 Feb;16(2):359-81.

• J Mol Biol. 2022 May 15;434(9):167559.

• J Mol Biol. 2020 Feb 14;432(4):878-896.

• J Mol Biol. 2015 Mar 27;427(6 Pt B):1316-1334.

• J Mol Biol. 2015 Jun 19;427(12):2229-43.

• J Mol Biol. 2011 Jul 15;410(3):411-23.

• J Mol Biol. 2010 Jan 22;395(3):491-503.

• Front Cell Infect Microbiol. 2018 Oct 5;8:352.

• J Biol Chem. 2021 Oct;297(4):101193.

• J Biol Chem. 2019 Sep 6;294(36):13233-13247.

• J Biol Chem. 2018 Oct 19;293(42):16142-16159.

• J Biol Chem. 2016 Aug 12;291(33):17283-92.

• J Biol Chem. 2016 Jul 1;291(27):14120-14133.

• J Biol Chem. 2015 Jan 2;290(1):601-11.

• J Biol Chem. 2015 Oct 23;290(43):26249-58.

• J Biol Chem. 2015 Oct 30;290(44):26856-65.

• J Biol Chem. 2007 Dec 21;282(51):37215-24.

• J Biol Chem. 2006 Dec 8;281(49):38061-70.

• J Biol Chem. 2012 May 4;287(19):15242-50.

• J Biol Chem. 2011 Apr 29;286(17):15344-51.

• J Biol Chem. 2011 Jul 22;286(29):26093-106.

• J Biol Chem. 2011 Jan 21;286(3):1966-75.

• J Biol Chem. 2011 Sep 30;286(39):34023-35.

• J Virol. 2015 Sep;89(17):8828-39.

• Structure. 2019 May 7;27(5):785-793.e5.

• Structure. 2010 May 12;18(5):638-48.

• Structure. 2010 Sep 8;18(9):1083-93.

• RNA. 2012 Nov;18(11):2020-8.

• Sci Rep. 2015 Oct 22;5:15660.

• Biochem J. 2018 Dec 19;475(24):3963-3978.

• Biochem J. 2016 May 1;473(9):1141-52.

• Proteins. 2015 Dec;83(12):2319-25.

• Proteins. 2015 Aug;83(8):1547-54.

• Proteins. 2015 Feb;83(2):383-8.

• Proteins. 2012 Oct;80(10):2469-75.

• Proteins. 2012 May;80(5):1495-9.

• Proteins. 2011 Aug;79(8):2566-77.

• Proteins. 2010 May 15;78(7):1631-40.

• Adv Protein Chem Struct Biol. 2008;75:85-105.

• J Bacteriol. 2016 Jul 28;198(16):2263-74.

• J Bacteriol. 2015 Nov 9;198(3):463-76.

• J Bacteriol. 2010 Jun;192(11):2746-56.

• Molecules. 2022 Apr 20;27(9):2655.

• PLoS One. 2017 Feb 3;12(2):e0171606.

• PLoS One. 2014 Jul 10;9(7):e101787.

• PLoS One. 2013;8(1):e52934.

• PLoS One. 2012;7(3):e33943.

• PLoS One. 2011 Mar 3;6(3):e16934.

• PLoS One. 2011;6(8):e14827.

• PLoS One. 2011;6(8):e22995.

• PLoS One. 2009 Oct 20;4(10):e7165.

• PLoS One. 2018 Dec 18;13(12):e0207563.

• Chembiochem. 2022 Jan 5;23(1):e202100414.

• Biochemistry. 2009 Nov 10;48(44):10542-8.

• Biochemistry. 2013 Sep 17;52(37):6525-36.

• Chembiochem. 2012 Nov 5;13(16):2408-15.

• J Struct Biol. 2010 Mar;169(3):304-11.

• Mol Biochem Parasitol. 2011 Oct;179(2):69-79.

• BMC Struct Biol. 2011 May 26;11:27.

• Acta Crystallogr F Struct Biol Commun. 2014 Oct;70(Pt 10):1318-23.

• J Struct Funct Genomics. 2014 Mar;15(1):33-40.

• Acta Crystallogr D Biol Crystallogr. 2013 Jun;69(Pt 6):1073-89.

• Acta Crystallogr Sect F Struct Biol Cryst Commun. 2013 Sep;69(Pt 9):956-61.

• Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Jan 1;68(Pt 1):89-92.

• Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Nov 1;68(Pt 11):1294-9.

• Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Nov 1;67(Pt 11):1399-402.

• Acta Crystallogr Sect F Struct Biol Cryst Commun. 2009 Mar 1;65(Pt 3):260-3.

• Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 Jun 1;64(Pt 6):554-7.

• Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008 Feb 1;64(Pt 2):98-101.

• bioRxiv. 2023 May 12;2023.04.19.537381.

• bioRxiv. January 23, 2023.

• bioRxiv. November 26, 2022.

• Journal of Molecular Biology. 2008 May 29, 379 (2):331-342.

• University of Saskatchewan. October 2008.

• Adam Mickiewicz University. Poznań, 2015.

• McMaster University. Oct-2013.

• McMaster University. Oct-2011.

• Queen’s University. September, 2010.

• Columbia University. January 22, 2014.

• Adam Mickiewicz University. 24-lip-2015.

• University of Calgary. 2021-01-29.

• Virginia Tech University. 2021-11-15.

• Virginia Tech University. 2013-06-11.

Recommended Reading

Selenomethionine Medium

selenoamino-acid-medium
Share：
Return
Relevant News
TAK-931 is a cancer therapeutic with a unique mechanism of action. Antitumor efficacy studies for TAK-931 were carried out at Medicilon
2023-08-21
Replication stress (RS) is a cancer hallmark; chemotherapeutic drugs targeting RS are widely used as treatments for various cancers. To develop next-generation RS-inducing anticancer drugs, cell division cycle 7 (CDC7) has attracted attention as a target. Researchers have developed an oral CDC7-selective inhibitor, TAK-931, as a candidate clinical anticancer drug. TAK-931 demonstrated marked, dose-dependent antitumor activity, without severe body weight loss. Antitumor efficacy studies for TAK-931 were carried out in two pancreatic PDX models, PHTX-249Pa and PHTXM-97Pa, at Medicilon.
Design, synthesis, and biological evaluation of potent PPARα/δ dual agonists for the treatment of nonalcoholic steatohepatitis. The PK studies, hERG studies, and Ames tests were conducted by Medicilon
2023-07-11
Nonalcoholic steatohepatitis (NASH) is the advanced subtype of nonalcoholic fatty liver disease (NAFLD) and is becoming a severe global public health problem. PPARα/δ are regarded as potential therapeutic targets for NASH. Herein, researchers report a series of novel triazolone derivatives as PPARα/δ dual agonists. The pharmacokinetic studies were conducted by Medicilon. The hERG channel inhibition studies were conducted by Medicilon. The Ames tests were conducted by Medicilon.
Discovery and synthesis of a new class of selective TNIK inhibitors and evaluation of their anti-colorectal cancer effects, the pharmacokinetic properties was carried out by Medicilon
2023-07-11
The Traf2- and Nck-interacting protein kinase (TNIK) is a downstream signal protein of the Wnt/β-catenin pathway and has been thought of as a potential target for the treatment of colorectal cancer. SAR analysis leads to the identification of a number of potent TNIK inhibitors with Compound 21k being the most active one. Preliminary assessment for the pharmacokinetic properties of Compound 21k was carried out through services provided by Medicilon.
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->